Vistagen Therapeutics (VTGN) Asset Utilization Ratio (2012 - 2026)
Vistagen Therapeutics (VTGN) posted Asset Utilization Ratio of 0.02 for Q1 2026, up 106.55% sequentially from 0.01 in Q4 2025, and up 306.28% YoY from 0.01 in Q1 2025.
Vistagen Therapeutics (VTGN) Asset Utilization Ratio (2012 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Asset Utilization Ratio for 11 years, with the latest figure at 0.02 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 306.28% year-over-year to 0.02 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02 (up 306.28% YoY) and the FY2026 annual result came in at 0.02, up 308.63% from the prior year.
- Asset Utilization Ratio rose to 0.02 in Q1 2026 per VTGN's latest filing, from 0.01 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.08 in Q2 2023 and troughed at 0.01 in Q1 2025.
- A 5-year average of 0.02 and a median of 0.01 in 2023 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio jumped 402.31% in 2023, then plunged 89.57% in 2024.
- Over 5 years, Asset Utilization Ratio stood at 0.04 in 2022, then slumped by 68.94% to 0.01 in 2023, then plunged by 42.89% to 0.01 in 2024, then soared by 51.03% to 0.01 in 2025, then jumped by 106.55% to 0.02 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.02, 0.01, and 0.01 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 0.13 |
| 10 | Vistagen Therapeutics | 10.66 Mn | 10.66 Mn | - | 0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.02 |
| Dec 31, 2025 | 0.01 |
| Sep 30, 2025 | 0.01 |
| Jun 30, 2025 | 0.01 |
| Mar 31, 2025 | 0.01 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.01 |
| Mar 31, 2024 | 0.01 |
| Dec 31, 2023 | 0.01 |
| Sep 30, 2023 | 0.03 |
| Jun 30, 2023 | 0.08 |
| Mar 31, 2023 | 0.06 |
| Dec 31, 2022 | 0.04 |
| Sep 30, 2022 | 0.03 |
| Jun 30, 2022 | 0.02 |
| Mar 31, 2022 | 0.01 |
| Dec 31, 2021 | 0.02 |
| Sep 30, 2021 | 0.01 |
| Jun 30, 2021 | 0.01 |